Erasca
ERASPhase 3Erasca, founded in 2018, is a public, clinical-stage biotech on a mission to 'erase cancer' by targeting the RAS/MAPK pathway, the most commonly mutated signaling cascade in cancer, affecting ~5.5 million new patients annually. The company has built a broad pipeline of small molecules, large molecules, and protein degraders targeting the pathway at multiple nodes. Led by a seasoned team with a track record in precision oncology, Erasca is strategically advancing combination regimens to overcome resistance and improve outcomes for patients with high-unmet-need cancers.
ERAS · Stock Price
Historical price data
AI Company Overview
Erasca, founded in 2018, is a public, clinical-stage biotech on a mission to 'erase cancer' by targeting the RAS/MAPK pathway, the most commonly mutated signaling cascade in cancer, affecting ~5.5 million new patients annually. The company has built a broad pipeline of small molecules, large molecules, and protein degraders targeting the pathway at multiple nodes. Led by a seasoned team with a track record in precision oncology, Erasca is strategically advancing combination regimens to overcome resistance and improve outcomes for patients with high-unmet-need cancers.
Technology Platform
A modality-agnostic platform focused on comprehensively shutting down the RAS/MAPK pathway through three strategies: clamping upstream/downstream nodes (MAPKlamp), direct RAS targeting, and blocking escape routes, utilizing small molecules, large molecules, and protein degraders.
Pipeline Snapshot
1010 drugs in pipeline, 1 in Phase 3
| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Naporafenib + Dacarbazine + Temozolomide + Trametinib | Advanced or Metastatic NRAS-mutant Melanoma | Phase 3 | |
| ERAS-007 + ERAS-601 | Advanced or Metastatic Solid Tumors | Phase 1/2 | |
| ERAS-007 + Encorafenib + Cetuximab + Palbociclib | Metastatic Colorectal Cancer | Phase 1/2 | |
| ERAS-007 + ERAS-601 + Gilteritinib | Acute Myeloid Leukemia | Phase 1/2 | |
| ERAS-801 | Glioblastoma Multiforme | Phase 1 |
Funding History
3Total raised: $464M
Opportunities
Risk Factors
Competitive Landscape
Erasca faces competition from major pharma (Amgen, Novartis, Pfizer) and biotechs (Revolution Medicines, Mirati) targeting individual nodes of the RAS/MAPK pathway. Its main differentiation is its integrated, multi-asset strategy (MAPKlamp) designed to overcome resistance by targeting the pathway comprehensively from within a single portfolio.
Company Info
Trading
Contact
Therapeutic Areas
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile